MG
ROIV icon

Michael Gelband’s Roivant Sciences ROIV Stock Holding History

Michael Gelband’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-632,908
Closed -$9.58M – 1987
2025
Q3 		$9.58M Buy
632,908
+228,164
+56% +$2.82M 0.1% 211
2025
Q2 		$4.56M Buy
404,744
+296,378
+273% +$3.21M 0.04% 454
2025
Q1 		$1.09M Buy
+108,366
New +$1.17M 0.01% 896
2024
Q3 		– Sell
-304,207
Closed -$3.21M – 2025
2024
Q2 		$3.21M Buy
+304,207
New +$3.33M 0.02% 597
2024
Q1 		– Sell
-36,262
Closed -$407K – 1899
2023
Q4 		$407K Buy
36,262
+947
+3% +$9.23K ﹤0.01% 1093
2023
Q3 		$412K Buy
35,315
+1,935
+6% +$21.9K ﹤0.01% 1303
2023
Q2 		$336K Sell
33,380
-454,708
-93% -$4.07M ﹤0.01% 1494
2023
Q1 		$3.6M Buy
488,088
+439,783
+910% +$3.62M 0.03% 635
2022
Q4 		$386K Buy
+48,305
New +$269K 0.01% 1271

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Michael Gelband's ROIV Position: Q4 2025 in Review

Michael Gelband sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 632,908 shares — an estimated $9.58M sold.

Michael Gelband first reported a position in ROIV in Q4 2022 and held it in 9 quarters. The position peaked at $9.58M in Q3 2025. 399 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

  • Michael Gelband reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
  • Michael Gelband sold 632,908 Roivant Sciences shares in Q4 2025, an estimated $9.58M.
  • Michael Gelband first reported a position in Roivant Sciences in Q4 2022 and held it in 9 quarters.
  • Michael Gelband's Roivant Sciences position peaked at $9.58M in Q3 2025.
  • 399 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.